Gilead gets EC approval for Sunlenca to treat multi-drug-resistant HIV
Gilead Sciences has secured the European Commission (EC) marketing authorisation for its long-acting HIV capsid inhibitor Sunlenca (lenacapavir) in injection and tablet formulation. The drug, together with other